Literature DB >> 22937934

Longitudinal analysis of hearing before and after radiosurgery for vestibular schwannoma.

Shoji Yomo1, Romain Carron, Jean-Marc Thomassin, Pierre-Hugues Roche, Jean Régis.   

Abstract

OBJECT: The aim of this study was to perform an accurate analysis of changes in hearing in patients with vestibular schwannoma (VS) who have undergone Gamma Knife surgery (GKS) and distinguish the impact of radiosurgery from the natural course of hearing deterioration due to the tumor itself.
METHODS: This study was a retrospective review of prospectively collected patient data. A group of 154 patients with unilateral nonsurgically treated VS was conservatively monitored for more than 6 months and then treated with GKS between July 1997 and September 2005. They were followed up with serial clinical examination, MRI, and audiometry. The annual hearing decrease rate (AHDR) was measured before and after radiosurgery, and the possible prognostic factors for hearing preservation were investigated.
RESULTS: The mean dose prescribed to the tumor margins was 12.1 Gy. The mean radiological follow-up period after GKS was 60 months (range 7-123 months). The tumor control rate was 94.8%, and 8 patients underwent subsequent intervention due to tumor progression. The mean audiological follow-up times before and after GKS were 22 and 52 months, respectively. The mean AHDRs before and after GKS were 5.39 dB/year (95% CI 3.31-7.47 dB/year) and 3.77 dB/year (95% CI 3.13-4.40 dB/year), respectively (p > 0.05). The mean pre- and post-GKS AHDRs in patients who initially had Gardner-Robertson (GR) Class I hearing were -0.57 dB/year (95% CI -2.95 to 1.81 dB/year) and 3.59 dB/year (95% CI 2.52-4.65 dB/year), respectively (p = 0.007). The mean pre- and post-GKS AHDRs in patients who initially had GR Class II hearing were 5.09 dB/year (95% CI 1.36-8.82 dB/year) and 4.98 dB/year (95% CI 3.86-6.10 dB/year), respectively (p > 0.05). A subgroup of 80 patients had both early and late post-intervention AHDR assessment (with early referring to the period from GKS to the assessment closest to the 2-year follow-up point and late referring to the period from that assessment to the most recent one); in these patients, the mean early post-GKS AHDR was 5.86 dB/year (95% CI 4.25-7.50 dB/year) and the mean late post-GKS AHDR was 1.86 dB/year (95% CI 0.77-2.96 dB/year) (p < 0.001). A maximum cochlear dose of less than 4 Gy was found to be the sole prognostic factor for hearing preservation.
CONCLUSIONS: The present study demonstrated the absence of an increase in AHDR after radiosurgery as compared with the preoperative AHDR. There was even a trend indicating a reduction in the annual hearing loss after radiosurgery over the long term. To fully elucidate a possible protective effect of radiosurgery, longer-term follow-up with a larger group of patients will be required.

Entities:  

Mesh:

Year:  2012        PMID: 22937934     DOI: 10.3171/2012.7.JNS10672

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  Hearing Preservation in Stereotactic Radiosurgery for Vestibular Schwannoma.

Authors:  Anthony M Tolisano; Jacob B Hunter
Journal:  J Neurol Surg B Skull Base       Date:  2019-01-10

Review 2.  The biology of radiosurgery and its clinical applications for brain tumors.

Authors:  Douglas Kondziolka; Samuel M Shin; Andrew Brunswick; Irene Kim; Joshua S Silverman
Journal:  Neuro Oncol       Date:  2014-09-28       Impact factor: 12.300

3.  Vestibular assessment in patients with vestibular schwannomas: what really matters?

Authors:  R Teggi; A Franzin; G Spatola; N Boari; P Picozzi; M Bailo; L O Piccioni; F Gagliardi; P Mortini; M Bussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-04       Impact factor: 2.124

Review 4.  The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature review.

Authors:  Carlotta Morselli; N Boari; M Artico; M Bailo; L O Piccioni; I Giallini; M de Vincentiis; P Mortini; P Mancini
Journal:  Neurosurg Rev       Date:  2020-02-06       Impact factor: 3.042

5.  Evaluation of Auditory Pathways Using DTI in Patients Treated with Gamma Knife Radiosurgery for Acoustic Neuroma: A Preliminary Report.

Authors:  Serpil Kurtcan; Mustafa Aziz Hatiboglu; Alpay Alkan; Huseyin Toprak; Mehmet Hakan Seyithanoglu; Ayse Aralasmak; Bahar Atasoy; Omer Uysal
Journal:  Clin Neuroradiol       Date:  2017-03-03       Impact factor: 3.649

6.  Modern Gamma Knife radiosurgery of vestibular schwannomas: treatment concept, volumetric tumor response, and functional results.

Authors:  Samuel M Lipski; Motohiro Hayashi; Mikhail Chernov; Marc Levivier; Yoshikazu Okada
Journal:  Neurosurg Rev       Date:  2014-12-19       Impact factor: 3.042

7.  Gamma Knife Radiosurgery for Large Vestibular Schwannoma More Than 10 cm 3 : A Single-Center Indian Study.

Authors:  Ujwal Yeole; A R Prabhuraj; Arimappamagan Arivazhagan; K V L Narasingarao; Vikas Vazhayil; Dhananjaya Bhat; Dwarakanath Srinivas; Bhanumathi Govindswamy; Somanna Sampath
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-23

8.  Long-Term Hearing Outcomes Following Stereotactic Radiosurgery in Vestibular Schwannoma Patients-A Retrospective Cohort Study.

Authors:  Peter L Santa Maria; Yangyang Shi; Richard K Gurgel; C Eduardo Corrales; Scott G Soltys; Chloe Santa Maria; Kevin Murray; Steven D Chang; Nikolas H Blevins; Iris C Gibbs; Robert K Jackler
Journal:  Neurosurgery       Date:  2019-10-01       Impact factor: 4.654

9.  Systematic Review of Hearing Preservation After Radiotherapy for Vestibular Schwannoma.

Authors:  Adam R Coughlin; Tyler J Willman; Samuel P Gubbels
Journal:  Otol Neurotol       Date:  2018-03       Impact factor: 2.311

10.  Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline.

Authors:  May N Tsao; Arjun Sahgal; Wei Xu; Antonio De Salles; Motohiro Hayashi; Marc Levivier; Lijun Ma; Roberto Martinez; Jean Régis; Sam Ryu; Ben J Slotman; Ian Paddick
Journal:  J Radiosurg SBRT       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.